These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
480 related articles for article (PubMed ID: 29165563)
21. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations. Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307 [TBL] [Abstract][Full Text] [Related]
22. Assessment of the in vitro activity of ceftazidime/avibactam against a global collection of multidrug-resistant Klebsiella spp. from the INFORM surveillance programme (2015-2017). Rossolini GM; Stone GG Int J Antimicrob Agents; 2020 Sep; 56(3):106111. PubMed ID: 32721602 [TBL] [Abstract][Full Text] [Related]
23. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055 [TBL] [Abstract][Full Text] [Related]
24. Changing Characteristics and Mavroidi A; Katsiari M; Likousi S; Palla E; Roussou Z; Nikolaou C; Mathas C; Merkouri E; Platsouka ED Microb Drug Resist; 2020 Jan; 26(1):28-37. PubMed ID: 31386596 [TBL] [Abstract][Full Text] [Related]
25. Molecular analysis of clinical isolates of ceftazidime-avibactam-resistant Klebsiella pneumoniae. Venditti C; Butera O; Meledandri M; Balice MP; Cocciolillo GC; Fontana C; D'Arezzo S; De Giuli C; Antonini M; Capone A; Messina F; Nisii C; Di Caro A Clin Microbiol Infect; 2021 Jul; 27(7):1040.e1-1040.e6. PubMed ID: 33775814 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of the synergy of ceftazidime/avibactam in combination with colistin, doripenem, levofloxacin, tigecycline, and tobramycin against OXA-48 producing Enterobacterales. Mataraci Kara E; Yilmaz M; Istanbullu Tosun A; Özbek Çelik B J Chemother; 2020 Jul; 32(4):171-178. PubMed ID: 32375606 [TBL] [Abstract][Full Text] [Related]
27. Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Shields RK; Chen L; Cheng S; Chavda KD; Press EG; Snyder A; Pandey R; Doi Y; Kreiswirth BN; Nguyen MH; Clancy CJ Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28031201 [TBL] [Abstract][Full Text] [Related]
28. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae? Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541 [TBL] [Abstract][Full Text] [Related]
29. The Potential Use of Ceftazidime-Avibactam Against Carbapenem Resistant Nasomsong W; Nulsopapon P; Changpradub D; Pongchaidecha M; Pungcharoenkijkul S; Juntanawiwat P; Simsiriporn W; Santimaleeworagun W Drug Des Devel Ther; 2021; 15():3095-3104. PubMed ID: 34295150 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of ceftazidime-avibactam in various combinations for the treatment of experimental osteomyelitis due to Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae. Davido B; Crémieux AC; Vaugier I; Gatin L; Noussair L; Massias L; Laurent F; Saleh-Mghir A Int J Antimicrob Agents; 2023 Jan; 61(1):106702. PubMed ID: 36476965 [TBL] [Abstract][Full Text] [Related]
31. Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum β-lactamases, and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant K. pneumoniae. Shields RK; Clancy CJ; Hao B; Chen L; Press EG; Iovine NM; Kreiswirth BN; Nguyen MH Antimicrob Agents Chemother; 2015 Sep; 59(9):5793-7. PubMed ID: 26169413 [TBL] [Abstract][Full Text] [Related]
32. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in Giddins MJ; Macesic N; Annavajhala MK; Stump S; Khan S; McConville TH; Mehta M; Gomez-Simmonds A; Uhlemann AC Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263067 [TBL] [Abstract][Full Text] [Related]
33. Evaluation of ceftazidime/avibactam alone and in combination with amikacin, colistin and tigecycline against Klebsiella pneumoniae carbapenemase-producing K. pneumoniae by in vitro time-kill experiment. Wang F; Zhou Q; Yang X; Bai Y; Cui J PLoS One; 2021; 16(10):e0258426. PubMed ID: 34648556 [TBL] [Abstract][Full Text] [Related]
34. Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies. Xu C; Wei X; Jin Y; Bai F; Cheng Z; Chen S; Pan X; Wu W Microbiol Spectr; 2022 Oct; 10(5):e0139022. PubMed ID: 35972286 [TBL] [Abstract][Full Text] [Related]
35. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S; Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404 [TBL] [Abstract][Full Text] [Related]
36. Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D Compain F; Arthur M Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461318 [TBL] [Abstract][Full Text] [Related]
37. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization. Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422 [TBL] [Abstract][Full Text] [Related]
38. Activity of Imipenem-Relebactam and Comparator Agents against Genetically Characterized Isolates of Carbapenem-Resistant Enterobacteriaceae. Canver MC; Satlin MJ; Westblade LF; Kreiswirth BN; Chen L; Robertson A; Fauntleroy K; La Spina M; Callan K; Jenkins SG Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31262761 [TBL] [Abstract][Full Text] [Related]
39. Ceftazidime/avibactam use for carbapenem-resistant Klebsiella pneumoniae meningitis: a case report. Holyk A; Belden V; Lee JJ; Musick W; Keul R; Britz GW; Lin J J Antimicrob Chemother; 2018 Jan; 73(1):254-256. PubMed ID: 29040635 [No Abstract] [Full Text] [Related]
40. In Vitro Activities of Ceftazidime-Avibactam, Aztreonam-Avibactam, and a Panel of Older and Contemporary Antimicrobial Agents against Carbapenemase-Producing Gram-Negative Bacilli. Vasoo S; Cunningham SA; Cole NC; Kohner PC; Menon SR; Krause KM; Harris KA; De PP; Koh TH; Patel R Antimicrob Agents Chemother; 2015 Dec; 59(12):7842-6. PubMed ID: 26392487 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]